GKOS Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of 12.68%. Glaukos Corp.'s return on equity of -11.73% beat Boston Scientific Corp.'s return on equity of 12.46%.

Glaukos Corp. has a consensus price target of $132.71, signalling upside risk potential of 24.33%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 44.07%. Given that Boston Scientific Corp. has higher upside potential than Glaukos Corp., analysts believe Boston Scientific Corp. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Glaukos Corp.'s net income of -$16.2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 38.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.88x versus 5.52x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of 27.89%. Glaukos Corp.'s return on equity of -11.73% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Glaukos Corp. has a consensus price target of $132.71, signalling upside risk potential of 24.33%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 27.84%. Given that Intuitive Surgical, Inc. has higher upside potential than Glaukos Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Glaukos Corp.'s net income of -$16.2M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 60.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.88x versus 17.25x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of -316.61%. Glaukos Corp.'s return on equity of -11.73% beat Plus Therapeutics, Inc.'s return on equity of --.

Glaukos Corp. has a consensus price target of $132.71, signalling upside risk potential of 24.33%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2040.08%. Given that Plus Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Glaukos Corp.'s net income of -$16.2M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.88x versus 4.12x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of 27.59%. Glaukos Corp.'s return on equity of -11.73% beat ResMed, Inc.'s return on equity of 25.44%.

Glaukos Corp. has a consensus price target of $132.71, signalling upside risk potential of 24.33%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 21.05%. Given that Glaukos Corp. has higher upside potential than ResMed, Inc., analysts believe Glaukos Corp. is more attractive than ResMed, Inc..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.60 per share. Glaukos Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Glaukos Corp. quarterly revenues are $133.5M, which are smaller than ResMed, Inc. quarterly revenues of $1.4B. Glaukos Corp.'s net income of -$16.2M is lower than ResMed, Inc.'s net income of $392.6M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while ResMed, Inc.'s PE ratio is 24.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.88x versus 6.69x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.